Monitor for future prospectus supplements that will disclose the specific terms of any offering, including security type, price, and size. The 'Baby Shelf' limitation suggests any single offering will likely be under $25 million, but the large shelf size indicates a potential for multiple capital raises, which could lead to significant shareholder dilution over time.
Price Chart
Executive Summary
PDS Biotechnology Corp filed an S-3/A shelf registration statement, authorizing the potential issuance of up to $200 million in securities, including common stock, preferred stock, debt securities, warrants, units, and rights. This filing updates market price information and removes a prior $20 million ATM offering, signaling the company's intent to access capital markets opportunistically in the future.
Key Financial Metrics
Key Facts
- PDSB filed an S-3/A shelf registration statement with an aggregate offering price of $200 million.
- The filing removes a prior $20 million ATM offering agreement.
- Proceeds are intended for product development, commercialization, and general corporate purposes.
- The company has a market cap of $50 million, making the $200 million shelf size significant at 400% of market cap.
- The public float is $73.99 million, and the company is subject to the 'Baby Shelf' limitation, restricting offerings to one-third of the public float ($24.66 million) in any 12-month period.
Financial Impact
Potential issuance of up to $200 million in securities, representing 400% of the current $50 million market cap.
Risk Factors
- Significant shareholder dilution if common stock is issued.
- Potential for multiple capital raises over the shelf's life, increasing dilution risk.
- Downward pressure on stock price if offerings are perceived as dilutive or opportunistic.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001140361-26-016756 |
| Document: ny20071147x1_ex107.htm | 0001140361-26-016756 |
| Document: ny20071147x1_ex5-1.htm | 0001140361-26-016756 |
| Document: ny20071147x1_ex23-1.htm | 0001140361-26-016756 |
| Document: 0001140361-26-016756-index-headers.html | 0001140361-26-016756 |
| Document: 0001140361-26-016756-index.html | 0001140361-26-016756 |
| Document: 0001140361-26-016756.txt | 0001140361-26-016756 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7366 (−145.53%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7366 (+252.61%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7366 (−215.87%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7366 (−186.61%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7366 (−2.95%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7366 (−18.07%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7366 (+23.27%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7366 (−27.78%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7366 (−36.50%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7366 (−44.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access